Hey readers!
Here's a finding that flips a long-held assumption: in celiac disease, the immune cells that drive the response may actually be quieter, not louder. That subtle difference could one day let clinicians spot risk before symptoms ever show up. This week we unpack that work, plus a wave of enzyme candidates aiming to disarm gluten, new numbers on autoimmune disease clustering in kids, and a fresh look at why some symptoms stick around despite a strict diet.
🧬 The T cell "momentum" story
The headline research this week comes out of Australia, and it challenges the tidy narrative that autoimmune disease is just an immune system stuck in overdrive.
New Study Links Celiac Disease Risk to Immune System Behaviour reports on work from WEHI and the Snow Centre for Immune Health looking at how CD4 helper T cells respond, store activation signals, and keep their "momentum" after the original trigger is removed. – A Gluten Free Family
Using a model called the Cyton 2 Cell Timer, the team switched cells on, pulled away every signal, and watched what happened next. In people with celiac disease, the CD4 helper T cells were the underachievers: less likely to survive, slower to divide, and producing less interleukin-2. The pattern held across age, sex, and whether someone was newly diagnosed or had lived with the condition for years.
"This tells us the effect isn't simply driven by inflammation or diet... It suggests an underlying inference that may be linked to genetic risk."
That last point is what makes this worth your attention. If the difference is baked into genetic risk rather than a downstream effect of eating gluten, it opens the door to identifying people at risk before the intestinal damage starts.
Test may help identify people at risk of celiac disease covered the same research on the Health Report and framed the practical upside plainly. – ABC listen
"Instead of being overactive, T cells in celiac disease were subdued, and didn't survive as long as T cells from healthy people."
The researchers describe the differences as "subtle but remarkably consistent," and suggest a test built on this could eventually flag risk for celiac disease and other autoimmune conditions. It's early, and no such test exists yet, but a consistent signal is exactly the kind of thing you want before building a screening tool.
👶 When autoimmune diseases travel in packs
If celiac risk is partly wired into immune behaviour, you'd expect it to show up alongside other autoimmune conditions. New data from Norway does exactly that.
More children are getting diseases like celiac disease, diabetes and Crohn's in Norway followed nearly 1 million children born between 2004 and 2019 and found 2.6% developed at least one autoimmune disease before age 18. Celiac disease was the most common, followed by type 1 diabetes and autoimmune thyroiditis. – The Lancet Child & Adolescent Health, via MedicalXpress
The study also found children who develop one autoimmune disease often go on to develop others, and it surfaced a geographic puzzle worth watching.
"Children in Northern Norway have a higher risk of getting three of these diseases than children living in Central Norway. The risk is lowest for children living the furthest south," Størdal says. "We are looking for an explanation as to why this is so."
For parents and clinicians, the takeaway is concrete: keep a low threshold for checking related conditions when symptoms suggest another organ system is involved. The researchers are exploring genetics, diet, environment, and antibiotic use as possible drivers, so nothing is settled yet.
A related Swedish study zooms in on one downstream risk that also seems to trace back to shared genetics.
Low Risk of Solid Organ Transplantation with Celiac Disease examined 41,277 people with biopsy-proven celiac disease and 196,863 matched comparators over a mean follow-up of 12.1 years. – gutsandgrowth
Transplants were more frequent in the celiac group (adjusted hazard ratio 2.76), with the strongest signal for liver transplantation (HR 7.26). Here's the reassuring context though: the absolute rate stayed low, at 17.0 per 100,000 person-years. The authors note that shared genetic susceptibility likely links celiac disease with autoimmune liver disease, but because risk was elevated even relative to unaffected siblings, celiac disease itself may add something beyond genetics.
💊 The race to disarm gluten
The genetic picture explains part of why a gluten-free diet remains the only real treatment. But several teams are chasing enzymes that break gluten down before it can provoke the immune response.
Celiac Disease: New Hope for a Pill Treatment? covers KumaMax, a re-engineered version of the enzyme kumamolisin-As designed to chop gluten into smaller, less-triggering peptides in the stomach. In test-tube work reported in the Journal of the American Chemical Society, it dismantled more than 95% of a gluten peptide thought to cause celiac disease. – Health Bulletin
Before anyone gets excited, the caveats are real and worth repeating to patients who ask.
"This is the earliest phase, and you now have to show that it actually breaks down the gluten peptides that trigger a response in the stomach at a speed that will protect the human," said Dr. Joseph Murray.
One expert even flagged that 95% breakdown may not be enough for everyone, and moving to safe, effective human use would take years.
A Barcelona group is pursuing a similar strategy with a different origin story.
Investigadores desarrollan un compuesto para evitar que el gluten desencadene la enfermedad celíaca describes "Celiacasa," an enzyme derived from studying a carnivorous plant, developed through CSIC and Universitat de Barcelona collaboration. – Telecinco
The compound is described as stable in the stomach's acidic environment and meant to be taken orally just before eating. In experimental models it reduced toxic gluten fragments by up to 99%, alongside less intestinal damage and lower immune-response markers. As with KumaMax, the team stresses that trials are still needed to confirm dose, tolerance, and long-term safety.
Meanwhile in India, a new grant takes aim at both diagnosis and a microbiome-based angle.
MDU, Rohtak secures Rs. 25 Lakh Grant for Advanced Celiac Disease Research funds a three-year project studying the prolidase enzyme and PEPD gene variations as potential biopsy-free diagnostic biomarkers, plus saliva microbes that could break down gluten. – City Air News
Prof. Amita Suneja Dang noted that there is currently no drug-based treatment for Celiac disease, and patients must rely on a gluten-free diet for their entire lives.
With cases described as rising across a North Indian "celiac belt" and diagnosis often delayed, the diagnostic-biomarker piece could matter as much as any therapy.
🔬 For patients still struggling on a gluten-free diet
Not every persistent symptom is a gluten slip-up, and one study offers a useful reminder for anyone frustrated that a strict diet hasn't solved everything.
Persistent Celiac Symptoms? New Study Points to Microbial Overgrowth found small intestinal microbial overgrowth is common in celiac disease, especially in refractory cases. – Celiac.com
Interestingly, the researchers found no clear link between bacterial overgrowth and Marsh score, meaning overgrowth might drive symptoms without explaining the villous damage itself. Breath testing and fluid culture also disagreed with each other. If digestive symptoms linger despite a clean diet, it's worth a conversation with a provider, keeping in mind the many other possible causes and the study's retrospective limits.
And a diagnostic note that reinforces long-standing practice:
Endoscopy Can Miss Key Digestive Diagnoses, Study Finds reported that in 100 patients, some lesions that looked benign on endoscopy turned out precancerous or cancerous under the microscope, with 88% overall accuracy for detecting such lesions. – Celiac.com
Duodenal biopsies picked up celiac-related changes in a subset of patients, underscoring that celiac diagnosis rests on history, blood testing, and biopsy together, not on how the tissue looks on a screen.
🧫 Around the neighborhood
A few developments in adjacent gut and immune conditions worth a scan:
Blood proteomics to identify childhood IBD risk narrowed 1,300 measured proteins to a four-protein blood test that identified IBD with 80-90% accuracy and distinguished ulcerative colitis from Crohn's with over 90% predictive performance. Fewer invasive procedures for kids is a goal worth cheering. – eBioMedicine
Dupilumab improves outcomes for eosinophilic gastritis showed objective improvements in a 41-patient phase 2 trial, with tissue-level gains continuing through 36 weeks and a familiar safety profile. – The Lancet Gastroenterology & Hepatology
Palisade Bio gets FDA IND clearance for PALI-2108, an oral PDE4 inhibitor prodrug for ulcerative colitis, with the Phase 2 ASCENTRA-UC trial (~204 patients) expected to enroll in the second half of 2026.
Agomab details its NOV-ERA Phase 2b study in fibrostenosing Crohn's, using endoscopic passability at Week 24 as its primary endpoint across up to 320 patients.
Jaguar Health reported ESPGHAN 2026 results for oral crofelemer in pediatric intestinal failure, including up to 48% reduction in weekly parenteral support normalized to body weight in one MVID patient after more than 12 months.
That's the issue. The through-line this week is that our understanding of the immune signature behind celiac disease is getting sharper, and with it, the case for earlier, less invasive detection. Take care of yourselves, and we'll see you next time.